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Letter to the EditorThe interferon gene signature is
increased in patients with early
treatment-naive rheumatoid
arthritis and predicts a poorer
response to initial therapyTo the Editor:
The interferon gene signature (IGS) is of increasing interest in
patients with autoimmune diseases. In patients with established
rheumatoid arthritis (RA), an IGS is present in approximately
20% of patients and associates with poor response to rituximab.1,2
Nevertheless, in patients with established RA, the IGS does not
associate with disease activity, and little is known regarding its
role in RA pathogenesis.3 However, glucocorticoids, which are
commonly administered in patients with RA, can modulate the
IGS,2 potentially confounding reported findings.
For the first time, we examined the IGS in glucocorticoid and
disease-modifying antirheumatic drug (DMARD)–naive patients
at their initial diagnosis of RA, as classified by a consultant
rheumatologist (early RA, n5 50; male/female ratio, 2:3; median
age, 57 years [range, 30-91 years]). Clinical parameters, including
autoantibody status, scores on the disease activity score for
rheumatic arthritis (DAS28) score and its components (erythrocyte
sedimentation rate [ESR] or C-reactive protein [CRP] level, tender
joint count, swollen joint count, and a patient-reported measure
[the visual analog scale]) were recorded. The DAS28was repeated
at 6 months (n 5 32), and drug history was recorded, including
glucocorticoid administration. Healthy control subjects with no
history of autoimmunity were also recruited (n5 23; male/female
sex, 1:1; median age, 36.5 years [25-62 years]), as were patients
with established (disease duration>12months) RA (n5 25;male/
female ratio, 2:3; median age, 68 years [range, 28-81 years]) and
systemic lupus erythematous (SLE; n5 23; male/female sex, 1:8;
median age, 55 years [range, 33-69 years]). Notably, disease
activity (DAS28 score), serostatus, ESR/CRP levels, age, and sex
were comparable between the early and established RA cohorts.
Full demographic data are shown in Table E1 in this article’s
Online Repository at www.jacionline.org.
Whole blood RNA (Tempus Spin RNA Isolation Kit; Thermo
Fisher Scientific, Waltham, Mass) was reverse transcribed to
cDNA with Superscript II (Thermo Fisher Scientific). RT-PCR
(TaqMan; Thermo Fisher Scientific) determined the expression of
MxA, IFI6, OAS1, ISG15, and IFI44L, the mean of which was
termed the IGS (full details are shown in Table E2 in this article’s
Online Repository at www.jacionline.org). Patients had a positive
IGS if their scorewas 2 ormore SDs greater than themean healthy
control IGS. Eleven patients with early RA had repeated longitu-
dinal IGS measurements at 1, 3, and 6 months after diagnosis.
Treatment for this cohort included a single baseline intramuscular
glucocorticoid depot (n 5 10) and methotrexate monotherapy
(n 5 8), hydroxychloroquine monotherapy (n 5 1), or both
methotrexate with hydroxychloroquine (n 5 2). Analysis used
GraphPad Prism software (version 5.0; GraphPad Software,
La Jolla, Calif) and JMP Statistical Visualization Software 2017 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. All rights reserved. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).(version 11; SAS Institute, Cary, NC). Significance was deter-
mined at a P value of less than .05. Age and sex had no effect
on IGS; nonetheless, all analyses were corrected for this.
IGS prevalence in our established RA and SLE cohorts was
similar to that in previous reportsE1,E2; however, there were twice
as many patients with a positive IGS among those with early RA
than among those with established RA (Fig 1, A). Indeed, the
mean IGS was significantly higher in patients with early RA
than in those with established RA (Fig 1, B). Corroborating this
observation, there was a significant and sustained decrease in
IGS in patients with early RA after 6 months of treatment
(Fig 1, C). At diagnosis (baseline), most patients received a depot
intramuscular glucocorticoid injection, but to reduce
confounding,2 we excluded from longitudinal IGS analysis
patients receiving additional glucocorticoids. Thus glucocorti-
coid exposure might have influenced the IGS at 1 month, but by
6 months, other factors will have contributed to the reduced
IGS. These could include reduced disease activity, as well as
direct DMARD effects, although the potential for drugs, such as
methotrexate, to modulate the IGS has not been appreciated
previously. However, we did not have adequate power in this
cohort to dissect the effects of different DMARDs on this
response. Nonetheless, the observed increased prevalence of
type 1 interferons in patients with early RA could mirror other
human autoimmune conditions in which early exposure can
reinforce aberrant signaling pathways and promote breach of
tolerance.4,5 Indeed, genetic variants associated with the type 1
interferon pathway, such as interferon regulatory factor 5,
increase RA susceptibility6; furthermore, IFN-a therapy can
induce a seropositive polyarthritis, and IGS in seropositive
patients with arthralgia has been reported to predict progression
to RA.7
Intriguingly, there was a significant association between
baseline IGS and contemporary DAS28 scores (Fig 1, D). This
observation was driven predominantly by the swollen joint
count and tender joint count DAS28 components (Fig 1, F).
However, in keeping with previous literature,3 there was no as-
sociation between DAS28 scores and IGS in patients with es-
tablished RA (Fig 1, E), thereby highlighting the potential
importance of examining the IGS in an early DMARD-naive
cohort. Others demonstrate a positive IGS, predicting an infe-
rior response to biological therapies in patients with estab-
lished RA1,2; however, we also demonstrated uniquely that in
patients with early RA, the IGS behaves as a prognostic
marker, predicting disease activity at 6 months (Fig 2, A).
Indeed, logistic regression confirmed a significant inverse asso-
ciation between baseline IGS and the probability of a good
European League Against Rheumatism (EULAR) response at
6 months despite treatment according to best current practice
(Fig 2, B). Finally, the baseline IGS also predicted additional
glucocorticoid administration in the initial 6 months after diag-
nosis (Fig 2, C). Crucially, baseline DAS28 scores and CRP/
ESR levels did not significantly predict these disease activity
outcomes (see Fig E1 in this article’s Online Repository at
www.jacionline.org). In other words patients with a higher
IGS were significantly less likely to respond well to initial
therapies, and this was independent of conventional disease ac-
tivity markers.1
FIG 1. IGS in patients with early RA: Prevalence and disease activity associations. Patients with early RA
(n5 50), established RA (n5 25), and established SLE (n5 23) and healthy control subjects (HC; n5 23) had
their whole blood IGS measured. A, Proportion of patients with a positive IGS in patients with early RA
(42%), established RA (21%), and SLE (56%). B, IGS expression across different disease cohorts. C, Patients
with early RA (n 5 11): longitudinal IGS expression at baseline (0 months) and 1, 3, and 6 months after
initiation of DMARD therapy. Gray shading depicts median IGS. Box and whisker plots show medians
and interquartile ranges. For both Fig 1, B and C, analysis included rank transformation of IGS scores, which
were tested for differences between groups after adjustment for age and sex with the Tukey multiple
comparison test applied. D and E, Plot depicts age- and sex-matched multiple regression between baseline
IGS and baseline DAS28 scores in patients with early (Fig 1, D) and established (Fig 1, E) RA. F, Swollen joint
count (SJC; P 5 .017) and tender joint count (TJC; P 5 .043) were the key drivers of association between
baseline DAS28 scores and baseline IGS. Multiple regression analysis: *P < .05, **P < .01, and ***P < .001.
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6 months despite itself falling during the intervening period.
Therefore type 1 interferon exposure might leave an early
‘‘imprint’’ (eg, an epigenetic modification) on pathways that
underpin disease activity, rendering them less responsive to
treatment. Indeed, in animal models type 1 interferon–produc-
ing dendritic cells promoted an inflammatory arthritis pheno-
type that persisted beyond the type 1 interferon production.8
Additionally, in patients with SLE, simultaneous Toll-like re-
ceptor 7/9 signaling in plasmacytoid dendritic cells, as well
as stimulating IFN-a release, causes relative glucocorticoidresistance.9 In that situation glucocorticoids can mask the
type 1 interferon/IGS response despite cellular resistance to
their anti-inflammatory and disease-modulating effects. These
examples illustrate that type 1 interferon exposure can estab-
lish or be associated with pathogenic pathways that are main-
tained independently of sustained type 1 interferon signaling.
Whether such mechanisms are involved in IGS-positive pa-
tients with early RA remains to be elucidated, but our data
are suggestive.
RA is highly heterogeneous, and we hypothesize that, in a
subgroup of patients with a susceptible genetic background, type
FIG 2. IGS in patients with early RA predicts worse disease activity, a poorer response to initial therapy, and
increased glucocorticoid requirements. Patients with early RA (n 5 32) had baseline IGS calculated and
disease activity parameters assessed at 6 months after diagnosis and initiation of treatment. A, Plot depicts
age- and sex-corrected multiple regression between baseline IGS and DAS28 scores at 6 months.
B, Relationship between the probability of achieving a good EULAR response at 6 months and baseline
IGS (nominal logistic regression, age and sex corrected). C, The plot depicts the relationship between the
probability of receiving additional glucocorticoids in the first 6 months after diagnosis and baseline IGS.
Numbers denote the number of additional glucocorticoid administrations (0-3) in the first 6 months.
Baseline IGS significantly predicted additional glucocorticoid requirements (ordinal logistic regression
with bootstrap probabilities included, P 5 .0003). The higher the baseline IGS, the greater the probability
that patients fall into the regions indicating 1 or more additional glucocorticoid doses.
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pathogenic pathways. This predicts lack of response to initial
treatment, as we demonstrate here, as well as a differential
response to later therapies.1,2 RA therapeutic strategies are
increasingly focused on early treatment and prompt disease
control. Therefore although validation of this work is required,
we suggest that in a subset of patients with RA at disease onset,
there could be future therapeutic merit in targeting type 1
interferon pathways.
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FIG E1. Additional prediction model figures. Patients with early RA (n 5 32) had baseline ESR levels, CRP
levels, and DAS28 scores calculated, and disease activity parameters were assessed at 6 months after
diagnosis and initiation of treatment. A, Plot depicts age- and sex-corrected multiple regression between
baseline ESR levels, CRP levels, and DAS28 scores and DAS28 scores at 6 months. B, Relationship between
the probability of achieving a good EULAR response at 6 months and baseline ESR levels, CRP levels, and
DAS28 scores (nominal logistic regression age and sex corrected). C, Plot depicts the relationship between
the probability of receiving additional glucocorticoids in the first 6 months after diagnosis and baseline ESR
levels, CRP levels, and DAS28 scores. Numbers denote numbers of additional glucocorticoid
administrations (0-3) in the first 6 months. Baseline ESR levels, CRP levels, and DAS28 scores did not
significantly predict additional glucocorticoid requirements (P 5 .345, P 5 .615, and P 5 .699, respectively;
ordinal logistic regression with bootstrap probabilities included).
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TABLE E1. Cohort demographics and clinical characteristics
Patients with
early RA
Patients with
established RA
Patients with
established SLE
Healthy control
subjects
Difference between
groups
No. 50 25 23 23 —
Age (y), median (range) 57.5 (30-91) 67.5 (28-81) 55 (33-69) 36.5 (25-62) P < .0001*
Male/female ratio 2:3 2:3 1:8 1:1 P < .0001*
Disease duration (y), median (range) — 10 (1-22) 10 (1-35) — —
DAS28 score, median (range) 4.36 (1.33-7.63) 5.25 (2.6-8.43) — — P 5 .104
CRP (mg/L), median (range) 7.5 (0-114) 8 (0-96) 5 (0-38) — P 5 .135*
ESR (mm/h), median (range) 22.5 (2-68) 25 (2-61) 27 (5-109) — P 5 .381*
RF1 and/or anti-CCP1, no. (%) 36 (72) 20 (87) — — P 5 .235
Patients receiving oral DMARDs, no. (%)§ 0 21 (91) 20 (87) — —
Patients receiving biological DMARDs, no. (%)§ 0 0 (0) 0 (0) —
Patients receiving glucocorticoids, no. (%)§ 0 3 (13) 6 (26) — —
Early RA only
Tender joint count, median (range) 4 (0-25)
Swollen joint count, median (range) 2 (1-24)
Patient VAS score, median (range) 57 (8-100)
Duration of symptoms (wk), median (range) 12 (3-52)
Early morning stiffness (min), median (range) 52.5 (0-380)
Data are expressed as medians (ranges) or numbers (percentages). Notably, there was no significant differences between early and established RA for age and sex (P > .2,
Tukey post hoc multiple comparison test).
anti-CCP, Anti-cyclic citrullinated peptide antibody; RF, rheumatoid factor; VAS, visual analog scale.
*One-way ANOVA.
Mann-Whitney U test.
x2 Test.
§Drug history data were recorded at the time of baseline IGS measurement.
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TABLE E2. RT-PCR
Gene
Primer
Roche Universal ProbeLibrary no.Forward Reverse
MxA GGAGAACATGGTGTGATAATCCT CACCGTGACACTGGGATTC 83
ISG15 GCGAACTCATCTTTGCCAGTA CCAGCATCTTCACCGTCAG 23
OAS1 CATCCGCCTAGTCAAGCACT CAGGAGCTCCAGGGCATAC 87
IFI6 CGGGCTGAAGATTGCTTCT AAAGCGATACCGCCTTCTG 25
IFI44L TGACACTATGGGGCTAGATGG GAATGCTCAGGTGTAATTGGTTT 15
Forward and reverse gene-specific primer sequences used for RT-PCR and probe numbers from the Roche Universal ProbeLibrary.
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